Brainsway stock surges after FDA clears accelerated depression treatment
PositiveFinancial Markets
Brainsway's stock price has surged following the FDA's approval of its accelerated treatment for depression. This breakthrough could provide new hope for patients struggling with this condition.
Editor’s Note: The FDA's clearance of Brainsway's treatment is significant as it may offer faster relief for those suffering from depression. This approval not only boosts the company's stock but also highlights advancements in mental health therapies.
— Curated by the World Pulse Now AI Editorial System